Invivyd (IVVD) Liabilities and Shareholders Equity (2020 - 2026)
Invivyd's (IVVD) quarterly Liabilities and Shareholders Equity came in at $218.9 million in Q2 2026, up 145.56% on a YoY basis from $89.1 million in Q2 2025, and down 20.95% quarter-over-quarter from $276.9 million in Q4 2025.
Analysis
Invivyd (IVVD) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $218.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 145.56% year-over-year to $218.9 million; the trailing twelve-month figure through Jun 2026 stood at $724.1 million (up 49.5% YoY), and the FY2025 full-year result was $276.9 million, up 113.78% from the prior year.
- Liabilities and Shareholders Equity retreated to $218.9 million in Q2 2026 per IVVD's latest filing, from $276.9 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $556.3 million in Q1 2022 and bottomed at $89.1 million in Q2 2025.
- Historically, Liabilities and Shareholders Equity has averaged $266.5 million across 5 years, with a median of $229.2 million in 2023.
- The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity sank 51.85% in 2025, then soared 145.56% in 2026.
- Over 5 years, Liabilities and Shareholders Equity stood at $383.2 million in 2022, then slumped by 40.19% to $229.2 million in 2023, then tumbled by 43.49% to $129.5 million in 2024, then surged by 113.78% to $276.9 million in 2025, then decreased by 20.95% to $218.9 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $218.9 million, $276.9 million, and $139.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 95.64 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 49.36 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 27.42 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 41.73 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 10.03 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 10.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 32.09 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | 218.88 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 218.88 Mn |
| Dec 31, 2025 | 276.88 Mn |
| Sep 30, 2025 | 139.16 Mn |
| Jun 30, 2025 | 89.14 Mn |
| Mar 31, 2025 | 103.74 Mn |
| Dec 31, 2024 | 129.52 Mn |
| Sep 30, 2024 | 161.92 Mn |
| Jun 30, 2024 | 177.35 Mn |
| Mar 31, 2024 | 215.47 Mn |
| Dec 31, 2023 | 229.18 Mn |
| Sep 30, 2023 | 274.92 Mn |
| Jun 30, 2023 | 315.41 Mn |
| Mar 31, 2023 | 350.56 Mn |
| Dec 31, 2022 | 383.17 Mn |
| Sep 30, 2022 | 424.75 Mn |
| Jun 30, 2022 | 484.61 Mn |
| Mar 31, 2022 | 556.27 Mn |
| Dec 31, 2021 | 620.09 Mn |
| Sep 30, 2021 | 686.27 Mn |
| Jun 30, 2021 | 397.99 Mn |